research Cetuximab-Associated Elongation of the Eyelashes
Cetuximab can cause eyelash growth, which is rare but manageable.
Search
for
Sort by
Research
390-420 / 1000+ results 
research Target-Adverse Events and Fear of Cancer Progression, Anxiety, and Depression in Patients with Advanced Non-Small Cell Lung Cancer
Adverse events in lung cancer treatments increase fear, anxiety, and depression, with newer therapies causing fewer side effects.
research [Efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer].
Pemetrexed with cisplatin is safer and more effective than gemcitabine with cisplatin for advanced lung cancer.
research SUN-911 Immunotherapy Use in Adrenocortical Carcinoma with Encouraging Results- a Case Report
Immunotherapy with pembrolizumab significantly reduced cancer in a young woman with adrenocortical carcinoma.
research 7410 Bevacizumab Induced Hypothyroidism
Bevacizumab may worsen hypothyroidism, so thyroid function should be monitored during treatment.
research Symptom Experience of Lung Cancer Patients Treated With Immunotherapy Combined with Chemotherapy: A Longitudinal Study
Lung cancer patients on immunotherapy and chemotherapy often experience severe fatigue, drowsiness, and appetite loss.
research Side Effects and Adverse Events After Treatment With Teprotumumab for Thyroid Eye Disease: A Retrospective Observational Case Series
Teprotumumab for thyroid eye disease commonly causes fatigue, brittle nails, dry eyes, hair loss, muscle spasms, and dry mouth, with rare serious events like blood clots.
research Synthesis, Anticancer and Molecular Docking Studies of 2-(4-chlorophenyl)-5-aryl-1,3,4-Oxadiazole Analogues
The compound 4c showed strong potential as an anticancer agent.
research Old drug new indication: Tofacitinib for a new crop of hair?
Tofacitinib might be used to treat hair loss.
research Inhibition of the development of metastatic squamous cell carcinoma in protein kinase C epsilon transgenic mice by alpha-difluoromethylornithine accompanied by marked hair follicle degeneration and hair loss.
Alpha-difluoromethylornithine prevents cancer in mice but causes hair loss.
research 532P Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011)
Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
research Trichomegaly of the eyelashes following treatment with cetuximab
Cetuximab can cause excessive eyelash growth.
research Moving Chemoprevention Forward into the Most Promising Areas of Study
Further research is needed to develop effective cancer prevention strategies.
research Induction of ornithine decarboxylase in specific subpopulations of murine epidermal cells following multiple exposures to 12-O-tetradecanoylphorbol-13-acetate, mezerein and ethyl phenylpropriolate
TPA strongly increases ODC activity in certain skin cells, potentially aiding tumor growth.
research Cyproterone acetate for severe hirsutism:results of a double‐blind dose‐ranging study*
Cyproterone acetate at 2mg daily is as effective as higher doses for treating excessive hair growth in women.
research Cancer vaccine strategies and studies of human thioredoxin reductase splice variants
Vaccines and targeting TrxR variants can help prevent cancer and reduce metastasis.
research Phase II Evaluation of VDC ‐1101 in Canine Cutaneous T‐Cell Lymphoma
VDC-1101 shows potential as a treatment for canine cutaneous T-cell lymphoma.
research Increased risk of telogen effluvium with tirzepatide compared to other weight-loss medications: a retrospective cohort TriNetX database study
research CUTANEOUS T-CELL LYMPHOMA
The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
research Streptomyces-derived nano-doxorubicin: Clinical status and patents granted
Nanoparticle delivery can reduce side effects of the cancer drug doxorubicin.
research SnapshotDx Quiz: September 2018
Tofacitinib may help regrow hair in alopecia areata patients.
research Targeted Therapy– and Chemotherapy-Associated Skin Toxicities: Systematic Review and Meta-Analysis
Minocycline reduces acne rash, pyridoxine lowers hand-foot syndrome risk, and scalp cooling lessens hair loss from cancer treatments.
research Vandetanib
A man developed alopecia areata after starting cancer treatment with vandetanib.
research Madarosis: a qualitative study to assess perceptions and experience of Australian patients with early breast cancer treated with taxane-based chemotherapy
Madarosis (eyebrow and eyelash loss) significantly affects quality of life for breast cancer patients on taxane-based chemotherapy.
research B/N-doped carbon nano-onions as nanocarriers for targeted breast cancer therapy
Boron/nitrogen-doped carbon nano-onions improve targeted breast cancer treatment by enhancing drug delivery and reducing side effects.
research Prophylaxis and Management of Skin Toxicities
Preventive measures and effective management are crucial for reducing skin side effects in cancer treatment.
research The protoporphyrin IX dimethyl ester incorporated soy lecithin for photoinactivation of fluconazole-resistant Candida albicans
research Trastuzumab Induced Chemobrain, Atorvastatin Rescued Chemobrain with Enhanced Anticancer Effect and without Hair Loss-Side Effect
Atorvastatin reversed memory problems caused by cancer drug trastuzumab and improved its cancer-fighting abilities without causing hair loss.
research Cetuximab-induced hypertrichosis of the scalp and eyelashes
A cancer drug caused unusual hair growth on a 100-year-old man's scalp and eyelashes.
research Health-related quality of life with sacituzumab govitecan in HR+/HER2− metastatic breast cancer in the phase III TROPiCS-02 trial
Sacituzumab govitecan improves quality of life and symptoms in breast cancer patients, except for causing more diarrhea.